Remove 2018 Remove Disease Remove Pharmaceuticals Remove Targeted Protein Degradation
article thumbnail

Evotec Achieves Key Milestones in Its Collaboration with Bristol Myers Squibb On Targeted Protein Degradation

The Pharma Data

Evotec and Bristol Myers Squibb (the successor in interest to Celgene ) initiated their long-term strategic drug discovery and development partnership in the field of targeted protein degradation in 2018 with the goal to identify novel drug targets.

article thumbnail

European drug discovery and development: success stories

Drug Discovery World

This growth is due to factors including a rise in speciality medicines, an increase in lifestyle-driven diseases and a growing population 1. France, Switzerland, and the United Kingdom have seen the fastest growth, accounting for 63% of the biotechs founded between 2018 and 2020.” Valued at $14.8 until 2030. Hotspots . References: .

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Brain organoids: a fascinating and powerful tool for drug discovery

Drug Target Review

Since brain organoids can be derived from either diseased or healthy patients, they can recapitulate human (patho)physiology making them a better choice compared to mammalian cell systems that often fail to recapitulate the human phenotype. Pharmaceutics. Pharmaceutics. 15(9):700-706 (2018) [link] Deshmukh V, et al.

article thumbnail

New trends in DNA-encoded library screening

Drug Discovery World

Targeted protein degradation and related modalities. A new modality where DEL screening has had particular impact is targeted protein degradation (TPD), a modality that has generated rapidly increasing interest in recent years. SLAS Discovery (2018). Brown DG, et al. Disch JS, et al.

DNA 130
article thumbnail

Antibody-drug conjugates payloads: then, now and next

Drug Target Review

Antibody-drug conjugates (ADCs) have been a groundbreaking approach to cancer treatment with their ability to deliver cytotoxic drugs directly to diseased cells while sparing healthy tissues. This targeted delivery allows enhanced therapeutic efficacy while reducing the harmful side effects commonly associated with traditional chemotherapy.